Work

Impact of Antiaggregant and Anticoagulant Medications on Perioperative Complications in Upper Tract Urothelial Carcinoma

Year: 2025

Type: article

Abstract: Our analysis of an extensive registry of patients with upper tract urothelial carcinoma revealed that anticoagulant and/or antiaggregant therapy is safe in the perioperative period for radical nephroureterectomy. We found no significant differences in either intraoperative or postoperative complication rates in comparison to a control group not receiving such therapy. Contemporary data are limited regarding the clinical practice of administering anticoagulant and antiplatelet medications (AA) perioperatively for patients with upper tract urothelial carcinoma (UTUC). Our aim was to investigate real-world AA perioperative management among patients with UTUC who underwent radical nephroureterectomy (RNU) and the impact on perioperative complications. We conducted a retrospective analysis of data from the Clinical Research Office of the Endourology Society UTUC registry. Patients were stratified into two groups according to perioperative AA use in the RNU cohort. Baseline characteristics were compared between the control and AA groups and intraoperative and postoperative complications were analyzed. We also conducted subgroup analysis for patients who discontinued AA use in comparison to those who continued AA therapy. Univariable and multivariable analyses were performed to identify predictors of perioperative complications. A total of 1264 patients who underwent RNU were included in the analysis. Of these, 393 (31%) had AA treatment before RNU and 871 (69%) did not. Intraoperative complications occurred in 23 patients (5.9%) in the AA group and 41 (4.7%) in the control group. Postoperative complications occurred in 101 patients (26%) in the AA group and 182 (21%) in the control group. Multivariable logistic regression demonstrated that AA was not an independent risk factor for either intraoperative complications (odds ratio 0.93, 95% confidence interval [CI] 0.48–1.83; p = 0.84) or postoperative complications (odds ratio 0.93, 95% CI 0.66–1.30; p = 0.66). Anticoagulant and antiaggregant therapy in patients undergoing RNU is safe, with no difference in the incidence of intraoperative and postoperative complications. Our analysis for patients with cancer in the upper urinary tract showed that taking drugs to prevent blood clots before surgery to remove a kidney is safe. We found no significant differences in complication rates in comparison to patients not taking these drugs. The Clinical Research Office of the Endourology Society UTUC registry study is registered on ClinicalTrials.gov as NCT02281188.

Source: European Urology Open Science

DOI: 10.1016/j.euros.2025.02.007